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Background: Tanzania has a high prevalence (7.17%) of chronic hepatitis B infection. Mother to Child transmission
is very common, resulting in high rate of chronic infections. Currently, there is no screening program for HBV in
pregnant women. This study investigated the prevalence and risk factors for chronic HBV infection in pregnant
women in a tertiary hospital in Mwanza, Tanzania.
Methods: Seven hundred and forty-three women attending antenatal care and/or delivering at the Bugando
Medical Centre were enrolled. All answered a questionnaire on sociodemographic and other risk factors and were
tested for HBsAg using a rapid test. In HBsAg positive mothers, maternal blood and umbilical cord blood samples
collected after delivery were analyzed for serological (HBsAg, HBeAg and anti-HBe) and virologic (HBV-DNA viral
load and genotype) markers. All their babies were vaccinated within 24 h of delivery. The children were followed up
at 3 years of age. Data was analyzed using the Mann-Whitney U-test, independent sample T-test and logistic
regression.
Results: Of the 743 participants, 22 (3%) were positive for HBsAg, and 2 (9%) had detectable HBe-antigen. Low
condom use was the only statistically significant risk factor for chronic HBV infection (OR = 3.514, 95%CI = 1.4–8.0).
Of 14 maternal blood samples genotyped, 10 (71%) were genotype A and 4 (29%) were genotype D. HBV-DNA was
detected in 21/22 samples, with a median of 241 IU/ml (range: 27.4–25.9 × 107 IU/ml). Five (33%) of 15 available
cord blood samples were positive for HBsAg and 10 (67%) were negative. At follow-up, one child showed chronic
HBV infection characteristics, one had anti-HBs level of 7 mIU/ml and 5/7(71%) had protective anti-HBs levels (> 10
mIU/ml).
Conclusion: This cohort of pregnant women showed a lower-intermediate prevalence of HBV of 3%. In the 3 years
follow-up only 1 out of 7 children showed evidence of chronic HBV infection. The child’s mother with high viral
load (25.9 × 107 IU/ml), was positive for HBeAg with a high degree of sequence similarity suggesting vertical
transmission. These results highlight a need for improved diagnosis and treatment of HBV infection in pregnant
women in Tanzania, in order to prevent vertical transmission.
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Around 257 million people worldwide are thought to
carry chronic hepatitis B virus (HBV) infection [1]. Al-
though HBV infection is preventable by vaccination, the
burden of chronic hepatitis B remains high. The “Global
Burden of Disease Study” found an overall increasing
trend in disability adjusted life years (DALYS) due to the
long-term sequelae of chronic hepatitis B (CHB), which
is in contrast to the general trend of decreasing burden
from other infectious diseases [2]. Projections indicate
that CHB may lead to additional 20 million deaths be-
tween 2015 and 2030 [3].
The highest prevalence of HBV infection is found in
the Western Pacific Region (6.2%), followed by the Afri-
can Region (6.1%) [1]. The prevalence of hepatitis B in
Tanzania varies from 3.8 to 8.0% according to different
studies and cohorts. A systematic review by Schweitzer
et al. estimates that the prevalence in Tanzania is higher
intermediate with overall 7.2% [4].
Recent studies on hepatitis B in pregnant women in
Tanzania showed HBV prevalence ranging from 3.8% in
a study in a district hospital in Mwanza [5], 3.9% in a
tertiary hospital in Dar es Salaam [6], 4.2% in a primary
health center in Moshi [7] to 8.03% in a municipal
health facility in Dar es Salaam [8].
In countries with high endemicity of CHB (≥8%) the
predominant routes of transmission are perinatal (>
20%) and early childhood infection (> 60%). By contrast,
in countries with low HBV endemicity (< 2%) adolescent
and adult infections are very common (70–90%), indicat-
ing a role for sexual transmission [9]. The risk of devel-
oping chronic infection decreases with age: children
infected in their first year have a high risk (80–90%),
which decreases to 30–50% in those before the age of 6
and to less than 5% in healthy adults [1].
Immunization is the cornerstone of effective preven-
tion for HBV transmission [1]. Vaccination with a 95%
efficacy has been available since 1982. In 2002, Tanzania
implemented HBV vaccination for children in the 4th,
8th and 12th week after delivery as part of the extended
program on immunization (EPI) [10]. Data published by
the WHO indicate a 97% coverage of three doses of
hepatitis B vaccination in 2017 in Tanzania [11]. How-
ever, low rates of HBs antibodies have been observed in
children [12, 13]. A hepatitis B vaccine birth dose has
not been implemented yet [14].
In resource-constrained settings recommended proce-
dures and diagnostics for the prevention of the mother
to child transmission (MTCT) of HBV are only partially
available for women due to the costs and lack of logis-
tics: the current situation in sub-Saharan Africa (SSA)
mirrors these deficiencies [15]. The application of hepa-
titis B immunoglobulin is not feasible in a setting where
general HBV testing of pregnant women is not in placeand also because of the high costs and the limited avail-
ability at primary health care centers [16].
Instead, a cost-effective alternative is the identification
of women at risk by rapid tests, and the administration
of the first dose of the HBV vaccine to the newborn
within 24 h of birth [15, 17, 18]. Rapid tests to detect
HBsAg in pregnant women have been proven reasonable
in detecting HBV infection in low-resource settings in
terms of accuracy, reliability, acceptance and perform-
ance [19]. Antiviral therapy with tenofovir in the later
state of pregnancy further reduces the risk of transmis-
sion and is recommended in regions were HBV viral
load testing is feasible [20]. Despite growing evidence on
the effectiveness of this intervention, the current WHO
guidelines do not recommend the use of antiviral ther-
apy to prevent MTCT. This is because intrauterine
transmission occurs comparably rarely and studies were
unable to show the cost-effectiveness [21].
This study aimed to understand the prevalence of HBV
infection in pregnant women in Mwanza, Tanzania, the
serological and virologic nature of the infection, as well as
identify possible risk factors.
Methods
Study design and setting
The cross-sectional study was conducted between Octo-
ber 2014 and March 2015 in the Department of Obstet-
rics and Gynaecology at Bugando Medical Medical
Centre (BMC) in Mwanza, Tanzania at the southern
shore of Lake Victoria. The follow-up of the children of
HBsAg positive women was conducted in February
2018. The BMC is the second-largest hospital in
Tanzania with 1000 beds taking care of 13 million
people as the referral hospital of the Lake Zone in
Tanzania. It is also a university teaching hospital with an
affiliated medical college.
Study population
All women who were about to give birth at the Bugando
Medical Centre were asked to participate in the study.
Additionally, women attending the antenatal care clinic
were asked to participate. Participation was voluntary
and without payment. Inclusion criteria were pregnancy
and 18 years of age or older. Exclusion criteria were
mental disorders.
Benefit for the study participant
Directly after birth, infant vaccination is one of the most
effective methods to reduce HBV transmission from the
infected mother to her child. Pregnant women giving
birth at the BMC got the opportunity to be tested for
free and, if positive, the HBV vaccine birth dose and
follow-up screening for the child were offered free of
charge.
Geffert et al. BMC Infectious Diseases          (2020) 20:395 Page 3 of 10At the time of the study, antiviral treatment for HBV-
infection using tenofovir was not yet licensed for the
treatment of HBV in Tanzania. Trained personnel were
available to inform the women about the disease and op-
portunities of secondary prevention. An information
sheet in Kiswahili including relevant facts about the dis-
ease and contact address for further follow-up was
handed over.
Assessment of socio-demographic data
A midwife collected information with a standardised ques-
tionnaire about self-reported HIV status, age, residence,
marital status, level of education, occupation, parity and
gravity, history of life-time sexual partners, age at first sex-
ual contact, history of risk factors (blood transfusion, sur-
gical operation, drug use, intravenous drug injection),
HBV vaccination, history of sexually-transmitted infec-
tions (STIs), condom use, female genital mutilation, shar-
ing of toothbrush or razors and history of jaundice in their
family or themselves. The patient data were collected at
the time of the enrolment in a case report form (CRF). A
copy remained at the investigator’s files. CRF and all ori-
ginal data were readily available for review during sched-
uled monitoring visits.
HBV analysis
Testing of pregnant women was performed using a
point-of-care HBsAg test (SureScreen, Derby, United
Kingdom). According to the manufacturer, sensitivity,
specificity and accuracy of the test are > 99% with a cut-
off value of 1 ng/mL HBsAg. Midwives were instructed
in the use of the HBsAg test and their performance was
monitored for 1 week by supervision and accompani-
ment during the testing and interview. Umbilical cord
blood sampling of the HBsAg positive mothers was con-
ducted by the midwives directly after birth. To avoid
contamination the first syringe was discarded and trans-
placental puncture was not recommended [22].
Plasma samples were frozen at − 20 °C for 6 months
before shipping to the Division of Medical Virology at
Stellenbosch University in Cape Town, South Africa for
further serologic and molecular testing. HBsAg status
was confirmed using the Murex HBsAg Version 3 kit
(Murex Biotech, Kent, England). HBeAg and anti-HBe
were assessed using DiaSorin ETI-EBK PLUS and ETI-
AB-EBK PLUS (DiaSorin, Salugia, Italy) respectively.
HBV DNA was extracted from plasma using the
QIAamp MinElute Virus Spin kit (QIAGEN, Hilden,
Germany). Quantitative polymerase chain reaction
(PCR) was performed on the Rotor-Gene 6000 according
to a previously described protocol with a lower limit of
quantification of 20 IU/ml [23]. Briefly, quantification of
HBV DNA was performed on the Bio-Rad CFX96 real-
time PCR detection system (Bio-Rad Laboratories,Hercules, CA) using the WHO HBV DNA quantification
standard (National Institute of Biological Standards and
Controls, Herts, UK) with a viral load of 1 × 106 IU/ml.
Samples with detectable HBV DNA were genotyped and
sequenced across the HBsAg gene and the overlapping
polymerase as previously described on the ABI-Prism-
3130xl genetic analyzer (Applied Biosystems, Foster, CA)
using the remaining extract from the quantitative HBV
DNA detection assay [24]. A nested PCR was performed
using the primers listed in Supplementary Table 1. Pres-
ence of product was visualized using gel electrophoresis.
The PCR products were cleaned up to remove and
underwent a sequencing reaction using the BigDye Ter-
minator v3.1 Cycle Sequencing Kit (Applied Biosystems,
California, USA). Sequencing reactions were then
cleaned up using BigDye XTerminator Purification Kit
(Applied Biosystems, California) in order to remove un-
incorporated terminators and before being loaded on the
genetic analyzer. Base calling was performed using
Sequencher and contiguous sequences exported. The
genotypes of the study participants were derived by
submitting the contiguous sequences onto online Gen-
o2pheno HBV subtyping database (https://hbv.geno2
pheno.org/index.php) of the Max Plancks Institute of In-
formatics (Saarbrücken, Germany).
Furthermore, viral sequence alignment was done using
ClustalW and phylogeny was inferred by using the
Neighbor Joining method based on the Tamura-Nei
model. Using MEGA6 software [25]. Reference se-
quences deposited on GenBank were downloaded and
used in the alignment and phylogenetic analysis. Se-
quences derived from this study have been submitted
onto GenBank (MN558930- MN558945).
Quality controls to exclude contamination during mo-
lecular assays was checked using nuclease free water as
non-template controls and negative human plasma from
a blood donor as a negative control for the extractions
and amplification reactions.Post-birth and follow-up
All children were vaccinated within 24 h after birth. For
the follow-up 3 years later, the HBsAg positive mothers
were contacted via mobile phone and recalled with their
children. Only 7/22 (32%) children were brought to the
follow-up visit. A whole blood sample was drawn from
the children, centrifuged at 3000 rpm (RPM) to separate
serum that was then frozen at − 20 °C for 10 months be-
fore shipping to the Department of Virology, University
of Wuerzburg, Germany, for further serologic and mo-
lecular analysis. In Germany, HBsAg testing was per-
formed using HBsAg qualitative II test on 2Architect
(Abbott, Ireland), HBV viral load with COBAS® Taq-
Man® using High Pure System (Roche, Switzerland).
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Data were entered into a Microsoft Excel database.
Statistical analyses were performed using IBM SPSS
Version 25 software. Quantitative variables are
expressed as mean ± standard deviation (SD). P-values
for variables with skewness and kurtosis outside the
range of [− 2;+ 2] were calculated using Mann-
Whitney U test, p-values for skewness and kurtosis
within the range of [− 2;+ 2] were calculated using the
independent sample T-test. Odds ratios, confidence
intervals and p-values were calculated using logistic
regression. A p-value of 0.05 or lower was considered
significant. For the models with a binary outcome of
zero, 0.5 was added to all numbers to generate a
hazard ratio.Results
Patient characteristics
A total of 743 women were recruited into the study. The
median age was 26 years (IQR: 31–22 = 9). According to
the questionnaire, 42 (5.7%) of the participants self-
reported to be HIV positive, while 17 (2.3%) did not
know their status. Only 5 (0.7%) patients had an HBV
test before.
Most of the participants lived in an urban area (710,
95.7%) and 689 (93.5%) were cohabiting or married. In
terms of maximum education level attained, primary
education was completed by 314 (42.4%) participants
and 389 (52.6%) completed secondary education and/or
went to college. Of 741 participants,1 429 (57.9%) were
employed, of which 26 (3.5%) were in the health sector.
The remaining 312 participants (42.0%) were not
employed and/or in a housewife role.
For 271 women (36.5%) it was the first pregnancy.
Of those included, 287 women (38.6%) reported they
had had only one sexual partner in their life, and the
vast majority, 712 (96.1%), reported they had their
first sexual contact above the age of 15. Only 14/701
(1.9%) reported receiving at least one dose of HBV
vaccination prior to enrolment into the study. The
majority, 733 (99.5%), sometimes or never used a
condom. Razor blades were shared more often than
toothbrushes (21.9% vs. 12.2%). Female genital mutila-
tion was reported in 23 cases (3.1%). Only a small
number (4.8%) reported a known history of sexual
transmitted infections (STIs). Of 716 participants, 556
(74.8%) had never had any contact with blood
containing risk factors such as blood donation, intra-
venous drugs and/or any infusion or injection (see
Table 1).1Information from 2 participants were missing.Laboratory results
Serology results
Of the 743 women tested, 22 (3.0%) were HBsAg posi-
tive when screened with the rapid test, which was con-
firmed using a laboratory-based assay. Of the 22 HBsAg
positive samples, 2 (9%) were HBeAg positive.
Umbilical cord blood samples from 15 babies born to
HBsAg positive mothers were available. Of these, 5/15
(33%) were tested positive for HBsAg. At 3 years post-
birth, a follow-up assessment was carried out on 7 (32%)
of the 22 children born to HBsAg positive mothers. The
other 15 children were lost to follow-up. Five (71%) of
the seven children that were followed up had protective
anti-HBs levels (> 10 mIU/ml). One child had anti-HBs
level of 7 mIU/ml. One of the seven children was HBsAg
positive and also positive for HBeAg, suggesting an
established hepatitis B infection.
Virologic results
HBV DNA was detectable in 21/22 of the HBsAg posi-
tive maternal blood samples. The median viral load
among those with detectable HBV DNA was 241 IU/ml
(IQR: 83–1730). Of the 14 samples obtained from the
pregnant women that were sequenced, 10 (71%)
belonged to HBV genotype A while 4 (29%) were geno-
type D (Fig. 1). Cord blood samples were not tested for
HBV DNA. The one HBsAg positive child at 3 years
follow-up (indicated as B1 in Fig. 1) had a hepatitis B
viral load of 6.3 × 107 IU/ml and was infected with HBV
genotype D. Pairwise distance analysis of the virus ob-
tained from the child’s (B1) and mother’s sample (M20
on Fig. 1) on a 593 bp fragment of the polymerase/sur-
face antigen region indicated no base differences per site
between the two sequences, indicating similarity. There
were no vaccine-escape mutations observed in the child-
derived sequence.
HBV and socio-demographic characteristics
Logistic regression indicated odds were higher for mothers
to be infected with HBV if they sometimes or never used
condoms (OR = 3.514, 95% CI = 1.4–8.0). HBsAg positivity
was seen in 2/42 (4.8%) of self-reported HIV-infected
cases compared to 20/678 (3.0%) of HIV-uninfected cases,
Fisher’s exact test p = 0.4 (see Table 2).
Discussion
Despite the reported higher intermediate prevalence of
hepatitis B infection in Tanzanian people [4], our study
cohort, pregnant women attending antenatal care or de-
livering at a tertiary hospital in Mwanza showed a low
intermediate prevalence of CHB with 22/723 (3%) being
HBsAg positive. This could be due to recruitment from
a tertiary hospital which induces a social selection bias
of the participants. The high percentage of completed
Table 1 Characteristics of participants (n = 743) according to HBsAg status
Total HBsAg positive HBsAg negative p-value
n (%) n (%) n (%)
Age (years), mean ± SD 26.98 ± 6.03 27.45 ± 5.4 26.97 ± 6.05 0.704
18–20 106 (14.3) 1 (4.5) 105 (14.6)
21–30 447 (60.2) 16 (72.7) 431 (59.8)
31–40 172 (23.1) 4 (18.2) 168 (23.3)
> 40 18 (2.4) 1 (4.5) 17 (2.4)
HIV statusa
HIV positive 42 (5.8) 2 (9.1) 40 (5.7) 0.509
HIV negative 678 (94.2) 20 (90.9) 658 (94.3)
Residenceb
Urban 710 (95.7) 21 (95.5) 689 (95.7) 0.957
Rural 32 (4.3) 1 (4.5) 31 (4.3)
Marital statusc
Single + Divorced + Widowed 48 (6.5) 3 (13.) 45 (6.3) 0.170
Cohabiting + Married 689 (93.5) 19 (86.4) 670 (93.7)
Educationd
Non-formal 37 (5.0) 1 (4.5) 36 36 (5.0) 0.845
Primary 314 (42.4) 9 (40.9) 305 305 (42.5)
Secondary + College 389 (52.6) 12 (54.5) 377 377 (52.5)
Worke
Health sector 26 (3.5) 2 (9.1) 24 24 (3.3) 0.080
Employed 403 (54.4) 14 (63.6) 389 389 (54.1)
Non employed/house wife 312 (42.1) 6 (27.3) 306 306 (42.6)
Gravidaf
One 271 (36.5) 10 (45.5) 261 261 (36.3) 0.199
Two or more 419 (59.4) 12 (54.5) 459 459 (63.7)
Parag
Zero 299 (40.3) 12 (54.5) 287 287 (39.9) 0.097
One or more 491 (59.7) 10 (45.5) 453 453 (60.1)
Number of sexual partner
One 287 (38.6) 7 (31.8%) 280 280 (38.8) 0.505
Two-three 372 (50.1) 12 (54.5) 360 360 (49.9)
Four or more 84 (11.3) 3 (13.6) 81 81 (11.2)
Age of first sexual contacth
Under 15 29 (3.9) 0 (0.0) 29 29 (4.0) 0.348
15 or above 712 (96.1) 21 (100) 691 691 (96.0)
HBV vaccinationi
Received at least one vaccination 14 (2.0) 0 (0.0) 14 14 (1.9) 0.507
No vaccination 687 (98.0) 21 (100) 666 666 (97.9)
History of STIsj
Yes 35 (4.8) 2 (9.1) 33 33 (4.6) 0.334
No 699 (95.2) 20 (90.9) 679 679 (95.4)
Condom usek
Always 4 (0.5) 0 (0.0) 4 4 (0.6) 0.725
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Table 1 Characteristics of participants (n = 743) according to HBsAg status (Continued)
Total HBsAg positive HBsAg negative p-value
n (%) n (%) n (%)
Sometimes + never 733 (99.5) 22 (100) 711 711 (99.4)
Female genital mutilationl
Yes 23 (3.1) 1 (4.5) 22 22 (3.1) 0.703
No 708 (96.9) 21 (95.5) 687 687 (96.9)
Sharing toothbrushm
Yes 91 (12.4) 3 (13.6) 88 88 (12.3) 0.856
No 644 (87.6) 19 (86.4) 625 625 (87.7)
Sharing razorn
Yes 162 (21.9) 3 (13.6) 159 159 (22.1) 0.342
No 578 (78.1) 19 (86.4) 559 559 (77.9)
History of jaundiceo
In the family 73 (9.9) 2 (9.1) 71 (9.9) 0.842
None 668 (90.1) 20 (90.9) 648 (90.1)
General risk from blood containing proceduresp
Risky procedure in the past 161 (22.5) 6 (27.3) 155 (22.3) 0.583
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national net enrollment rate of secondary education of
23% in 2017 [26], is also an indicator of possible social
selection bias. However, another study found a compar-
able prevalence of HBsAg among women delivering in
primary health care settings in the area of Mwanza [5],
which typically do not charge for user fee. This may in-
dicate a lower prevalence in this area compared to the
rest of Tanzania where a prevalence of 7.17% has been
reported [4]. Given a lack of standard therapy for pa-
tients with chronic HBV infection accessible in Tanzania
[10], even this low percentage presents a problem for pa-
tients, relatives and the health-care system alike. Hepa-
titis B prevalence disparities among pregnant women
between regions within a country have also been re-
ported in other SSA countries. In Kenya, where the na-
tional hepatitis B prevalence among pregnant women
was 9.3%, intradistrict HBV prevalence disparities ranged
between 4.3 and 17.8% [27]. Similarly, in Nigeria largelocal differences in HBV prevalence have been ob-
served [28].
Factors which have been found to be associated with
HBsAg positivity in other Tanzanian and African studies
include multigravidity, urban residence, younger age
(15–24 years), presence of other sexually transmitted dis-
eases, history of blood transfusions, oral contraceptives
use, anemia, body tattooing and unsafe injections [5, 29,
30]. In our study, only the characteristic of no or some-
times condom use shows a statistically significant higher
association (OR = 3.514, p = 0.008) with a positive
HBsAg result. However, given only four participants in-
dicated the use of condoms as ‘always’, our results need
to be interpreted with care. Additionally, as we were
looking at pregnant women, it is unlikely that the con-
dom use was consistent and there might be a bias in the
classification, as well as the responses. The lack of sig-
nificance for other characteristics may be due to the
small number of HBsAg positive cases that could
Fig. 1 Molecular Phylogenetic analysis by Neighbour Joining method. The evolutionary history was inferred by using the Maxi Neighbour Joining
method based on the Tamura-Nei model. Sequences derived from mothers samples are prefixed by M- and annotated with a black square while
the single child-derived sequence is denoted as B1 and annotated with a red triangle. Sequences from the study were aligned against other HBV
sequences deposited on GenBank
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Therefore, additional studies with larger sample sizes are
necessary to confirm these results.
Two women were positive for HBeAg, which usually
indicates high viral replication. One of these women (see
Table 2; number 20) had the highest viral load of 25.9 ×
107 IU/ml. In the follow-up her child was positive for
HBsAg, HBeAg and anti-HBc and had a viral load of
6.3 × 107 IU/ml. Even though no other sample from this
child is available, it is very likely that these results indi-
cate CHB resulting from a vertical transmission. Indeed,
the phylogenetic relationship and pairwise distance ana-
lysis showed identical nucleotide bases across the se-
quenced polymerase region of the virus derived from the
mother’s and the child’s blood. It could be argued thatthe recommendation to use tenofovir in highly-viraemic
HBV-infected pregnant women within the third trimes-
ter might have helped to prevent infection in the child
[31]. Unfortunately, tenofovir was not licensed in
Tanzania at the time of enrollment for this study. Ad-
ministration of vaccine alone was not enough to prevent
infection in the child. Our results show that the strain
that infected the child was amenable to vaccination be-
cause no mutations that may be associated with vaccine
escape were detected. This therefore rules out the possi-
bility that the child could have been infected due to vac-
cine failure.
Two other mothers had a viral load > 2000 IU/ml
which represents an indication for treatment for CHB
[21]. Both of their children had HBsAg positive cord
Table 2 Logistic Regression of characteristics and HBV infection
(n = 743)
OR 95% CI p-value
Age of the participants (years)
18–20 1 0.480
21–30 3.898 0.511 29.724
31–40 2.500 0.276 22.672
> 40 6.176 0.369 103.494
HIV status
HIV positive 1.645 0.371 7.286
HIV negative 1 0.512
Residence
Urban 1 0.956
Rural 1.058 0.138 8.124
Marital status
Single + Divorced + Widowed 2.351 0.671 8.242 0.182
Cohabiting + Married 1
Education
Non-formal 1 0.981
Primary 1.062 0.131 8.629
Secondary + College 1.146 0.145 9.067
Work
Health sector 4.250 0.813 22.204
Employed 1.835 0.697 4.832
Non employed/house wife 1 0.194
Gravida
One 1.466 0.625 3.439 0.380
Two or more 1
Para
Zero 1.810 0.772 4.246 0.172
One or more 1
Number of sexual partners
One 1 0.791
Two-three 1.333 0.518 3.431
Four or more 1.481 0.375 5.859
Age of first sexual contact
Under 15 1.834 0.750 4.486 0.184
15 or above 1
HBV vaccination
Received at least one vaccination 1
No vaccination 1.069 0.434 2.634 0.884
History of STIs




Table 2 Logistic Regression of characteristics and HBV infection
(n = 743) (Continued)
OR 95% CI p-value
Sometimes + never 3.514 1.382 8.036 0.008
Female genital mutilation
Yes 1.487 0.191 11.557 0.705
No 1
Sharing toothbrush




No 1.801 0.526 6.165 0.348
History of jaundice
Family or myself 1
None 1.096 0.251 4.785 0.903
General risk from blood contact
Risky procedure in the past 1.307 0.503 3.396 0.5833
No risky procedure in the past 1
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follow-up. Follow-up was only possible for one child
with HBsAg positive and six with HBsAg negative umbil-
ical cord blood samples at birth. At follow-up, 5/7 had
protective anti-HBs levels and no anti-HBc indicating suc-
cessful vaccination and no exposure to natural infection.
Many children born to HBV-infected mothers were lost to
follow-up because we could not contact the mothers due
to change of mobile phone numbers, relocation to other
areas away from the study site and in some cases, inability
to come to the hospital for other reasons.
The observation that 5 out of 15 cord blood samples were
positive for HBsAg needs to be interpreted with caution,
because of the high risk of contamination with maternal
blood during delivery. This could explain one child having
HBsAg positive umbilical cord blood, but no HBsAg posi-
tivity in the follow-up. The high workload of the health-
care workers also led to the low number of women re-
cruited for the study (compared to the number of deliveries
taking place) and missing cord blood samples. Additionally,
a presence of HBsAg in cord blood does not necessarily re-
flect an infection with HBV and merely indicates an expos-
ure, as a recent study by Liu et al. has shown [32].
The HBV genotype varies according to the geographic
region: genotype A is mainly found in southern, eastern
and central Africa while genotype D is predominant in
northern and genotype E in western Africa [33]. Our se-
quencing results and phylogenetic analysis by maximum
likelihood showed a high prevalence of genotype A (71,
4%), and a low prevalence of genotype D (28,6%) in line
with previous findings in Tanzania [34]. Genotype A may
Geffert et al. BMC Infectious Diseases          (2020) 20:395 Page 9 of 10have a more severe disease outcome rather than D, but
further studies are needed to investigate this [33, 35].
A methodological limitation of our study is the use of
HBsAg rapid testing as the only screening method for
CHB, as it misses occult HBV infections. Due to muta-
tions of the HBV surface antigen gene occult infections
cannot be detected by common HBsAg tests [36]. The
method of choice to detect occult HBV infections is real
time PCR but this was not available at the study site.
Allain et al recently highlight the prevalence of occult
HBV infection in general population ranges between
1:100–1000 in high prevalence areas of West Africa and
Asia [37]. Therefore, we estimate that missed cases of
occult HBV infection did not considerably influence our
study results. The missing values of some of the charac-
teristics of participants (Table 1), as well as the high
number of the loss to follow-up are another limitation of
the study. A more comprehensive collection of data
could have allowed a better, more precise analysis.
Another general limitation of this assessment is the so-
cial desirability bias, especially in the context of sexual be-
havior. Another limitation is the high possibility of recall
bias, especially for questions on previous injections and
other medical treatments. This means that the results of
the analysis of the patient characteristics need to be inter-
preted with caution, because of possible low or wrong
answers (e.g. on the number of sexual partners, the age of
first sexual contact, number of medical interventions).
The specific study group does not allow an extrapolation
to pregnant women in general in Tanzania.
Conducting a study on Hepatitis B infection in a setting
where no medical treatment is available brings up ethical di-
lemmas that need to be considered cautiously. Even though
it was not possible to provide the women themselves with
treatment for their infection, the diagnosis may have in-
creased their awareness for this infection and thereby
possibly contributed to the reduction of transmission.
Conclusion
The HBsAg prevalence of 3% among 743 pregnant women
in this study conducted at a tertiary hospital in Mwanza
was lower compared to other studies on pregnant women
[5–8], or the general population in Tanzania [4]. In the
follow-up 3 years later only one (14%) of seven children
showed evidence of chronic HBV infection. The mother
of the child had a high viral load (25.9 × 107 IU/ml) and
was positive for HBeAg and is likely to have been the
source of infection in the child, as revealed by the similar-
ity of their viral sequences. With no standard therapy for
CHB accessible in Tanzania, even this comparably low
number of cases indicate a problem for the women and
their children. We suggest screening of pregnant women
and newborn vaccination should be implemented to pre-
vent newborns from infection.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12879-020-05096-2.
Additional file 1: Table S1. Oligonucleotide primers used for the
nested PCR amplification of the HBV polymerase gene. Table S2. HBsAg
positive participants and laboratory results (n = 22).
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